PMTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PMTS is not a good buy right now for an impatient investor. Despite improving YoY earnings and heavy insider buying, the chart trend is still bearish (downtrend structure, weakening momentum) and there are no near-term catalysts or proprietary buy signals to justify an immediate entry. A better setup would be a confirmed reversal back above key resistance (~13.56) or improving momentum indicators.
Trend/momentum: Bearish. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD histogram is negative (-0.0619) and negatively expanding, suggesting downside momentum is still building rather than stabilizing. Overbought/oversold: RSI_6 is 29.31, which is near oversold and can support a short-term bounce, but it is not a reliable buy signal on its own when trend and MACD remain bearish. Key levels: Current price 12.76 is essentially sitting on S1 (12.756). A clean break below increases risk toward S2 (12.258). Reclaiming the pivot (13.562) would be the first meaningful technical improvement; next resistance levels are 14.368 and 14.866. Pattern-based odds: The comparable-pattern model suggests modest upside over a month (+4.05%), but near-term edge is small (+0.61% next day; +0.21% next week) and doesn’t outweigh the current bearish momentum.
Insiders are buying aggressively (buying amount up ~1802.83% over the last month), which is a strong confidence signal.
Latest reported quarter (2025/Q3): Revenue +10.59% YoY, Net Income +78.50% YoY, EPS +72.73% YoY.
Wall Street stance remains constructive: multiple firms maintain Buy ratings and explicitly mention buying on weakness / valuation near a trough.
Hedge funds are neutral (no notable selling pressure flagged).
Technical setup remains bearish: downtrend MA stack and worsening MACD momentum.
Profitability pressure: Gross margin fell to 28.62% (down 17.88% YoY), consistent with mix/tariff/startup cost headwinds.
Guidance/expectations risk: Analysts cited trimmed 2025 revenue/EBITDA growth outlook and tariff impacts.
No news-driven catalyst in the last week to spark an immediate reversal.
Latest quarter: 2025/Q3. Growth: Revenue rose to $137.97M (+10.59% YoY), Net Income increased to $2.31M (+78.50% YoY), EPS improved to $0.19 (+72.73% YoY). Quality of growth / margins: Gross margin declined to 28.62% (-17.88% YoY), signaling cost/mix pressures even as earnings rose—good bottom-line momentum, but margin trend is a key negative to watch.
Recent trend: Ratings stayed at Buy across the covered updates, but price targets were cut meaningfully (B. Riley $34→$28; DA Davidson $32→$30; Lake Street $30→$25; Roth $40→$30) after Q3 and amid tariff/mix/startup-cost headwinds. Wall Street pros: Maintained Buy ratings, view valuation as near a trough, and some recommend buying weakness. Wall Street cons: Organic growth softness (noted contraction), gross margin/mix pressure, tariffs, and a slightly reduced 2025 outlook. Influential/congress trading: No recent congress trading data available; no politician activity provided.
